Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States
- 7 May 2019
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 214, 77-87
- https://doi.org/10.1016/j.ahj.2019.04.020
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Effects of a Fixed-Dose Combination Strategy on Adherence and Risk Factors in Patients With or at High Risk of CVDJAMA, 2013
- Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in ArgentinaBMC Public Health, 2010
- Hypercholesterolemia and Myocardial function evaluated via Tissue Doppler ImagingCardiovascular Ultrasound, 2009
- A systematic review and meta-analysis on the therapeutic equivalence of statinsJournal of Clinical Pharmacy & Therapeutics, 2009
- Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBMJ, 2009
- Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, ArgentinaCost Effectiveness and Resource Allocation, 2009
- The polypill: at what price would it become cost effective?Journal of Epidemiology and Community Health, 2006
- Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery DiseaseCirculation, 2006
- Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ, 2003
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998